Janssen Pharmaceutical K.K. Clinical Trial
Janssen Pharmaceutical K.K.
Built from public records under this name as ClinicalTrials.gov spells it. A name can belong to more than one person, so each section says how its rows were tied to this name. No contact details are shown.
Registry trials as an overall official
40
all conditions, ClinicalTrials.gov
NIH grants tied to them
0
NIH RePORTER
Trial papers in multiple myeloma
0
PubMed author-name match
Trials
Studies that name Janssen Pharmaceutical K.K. Clinical Trial as principal investigator, study chair or study director, newest first. Live from ClinicalTrials.gov, fetched 2026-11-12 13:41 UTC. Open this list on ClinicalTrials.gov
- Ph3NCT05167825 · A Study of Macitentan in Japanese Pediatric Participants With Pulmonary Arterial HypertensionJanssen Pharmaceutical K.K. · completed · Pulmonary Arterial Hypertension · study director
- Ph1NCT03618160 · A Study to Assess the Safety, Tolerability and Pharmacokinetics of Subcutaneous (SC) Injections of JNJ-64565111 in Healthy Male Japanese Participants and to Assess Pharmacokinetics Following Subcutaneous Injections of JNJ-64565111 in Healthy Male Caucasian ParticipantsJanssen Pharmaceutical K.K. · terminated · Healthy
- Ph1NCT02835508 · Pharmacokinetic Study of JNJ-56021927 When Taken Orally as Tablet Formulation in Healthy Male Japanese ParticipantsJanssen Pharmaceutical K.K. · completed · Healthy · study director
- Ph3NCT02641730 · An Efficacy and Safety of Guselkumab in Participants With Palmoplantar PustulosisJanssen Pharmaceutical K.K. · completed · Palmoplantar Pustulosis · study director
- Ph1NCT02497378 · A Study of JNJ-54767414 (Daratumumab) in Combination With Bortezomib and Dexamethasone (D-Vd) in Japanese Participants With Relapsed or Refractory Multiple MyelomaJanssen Pharmaceutical K.K. · completed · Multiple Myeloma · study director
- Ph2NCT02365623 · An Exploratory Study of TMC207 in Japanese Participants With Pulmonary Multi-Drug Resistant Tuberculosis (MDR-TB)Janssen Pharmaceutical K.K. · completed · Tuberculosis, Multidrug-Resistant · study director
- Ph1NCT01371227 · A Study of JNS002 (Doxorubicin Hydrochloride Liposome Injection) in Relapsed or Refractory Multiple MyelomaJanssen Pharmaceutical K.K. · completed · Multiple Myeloma · study director
- Ph3NCT01366638 · A Study of TMC435 in Participants With Genotype 1 Hepatitis C Virus (HCV) InfectionJanssen Pharmaceutical K.K. · completed · Hepatitis C, Chronic · study director
- Ph3NCT01357993 · A Long-Term Study on Safety of JNS001 in Adults With Attention-Deficit Hyperactivity DisorderJanssen Pharmaceutical K.K. · completed · Attention-Deficit / Hyperactivity Disorder · study director
- Ph3NCT01323192 · An Efficacy and Safety Study for JNS001 in Adults With Attention-Deficit Hyperactivity DisorderJanssen Pharmaceutical K.K. · completed · Attention-Deficit Hyperactivity Disorder · study director
- Ph3NCT01309386 · A Safety and Efficacy Study of Oral Tapentadol Extended-Release in Japanese ParticipantsJanssen Pharmaceutical K.K. · completed · Neoplasms · study director
- Ph1NCT01309412 · A Phase 1 Study of CNTO 328 (Siltuximab) in Relapsed or Refractory Multiple MyelomaJanssen Pharmaceutical K.K. · terminated · Multiple Myeloma · study director
- Ph3NCT01299389 · An Efficacy and Safety Study of Paliperidone Palmitate in Participants With SchizophreniaJanssen Pharmaceutical K.K. · completed · Schizophrenia · study director
- Ph3NCT01292239 · A Phase III Study of TMC435 in Treatment-naive, Genotype 1, Hepatitis C-infected PatientsJanssen Pharmaceutical K.K. · completed · Hepatitis C, Chronic · study director
- Ph3NCT01290731 · A Study of TMC435 in Genotype 1, Hepatitis C-infected Patients Who Relapsed After Previous Interferon (IFN)-Based TherapyJanssen Pharmaceutical K.K. · completed · Hepatitis C, Chronic · study director
- Ph3NCT01288209 · A Phase III Study of TMC435 in Genotype 1, Hepatitis C-infected Participants Who Failed to Respond to Previous IFN-based TherapyJanssen Pharmaceutical K.K. · completed · Hepatitis C, Chronic · study director
- Ph3NCT01258920 · A Study of Paliperidone Palmitate in Japanese Patients With SchizophreniaJanssen Pharmaceutical K.K. · completed · Schizophrenia · study director
- Ph2NCT01124604 · An Efficacy and Safety Study for Tapentadol Extended Release (JNS024ER) in Chronic Pain ParticipantsJanssen Pharmaceutical K.K. · completed · Pain, Low Back Pain, Back Pain · study director
- Ph2NCT01081795 · A Dose-Finding Study of Topiramate (JNS019) in Participants With MigraineJanssen Pharmaceutical K.K. · completed · Migraine · study director
- Ph2NCT00996476 · A Study to Assess the Effectiveness, Safety, and Pharmacokinetics of TMC435 in Combination With Peginterferon Alfa-2a and Ribavirin in Hepatitis-C Infected PatientsJanssen Pharmaceutical K.K. · completed · Hepatitis C, Chronic · study director
- Ph3NCT00814801 · An Efficacy and Safety Study of Galantamine for the Treatment of Patients With Alzheimer's DiseaseJanssen Pharmaceutical K.K. · completed · Alzheimer's Disease · study director
- Ph3NCT00771251 · A Safety and Efficacy Study of Golimumab (CNTO148) in Patients With Active Rheumatoid Arthritis (RA)Janssen Pharmaceutical K.K. · completed · Rheumatoid Arthritis · study director
- Ph1/Ph2NCT00752518 · A Japan Phase I/II Study of Bortezomib in Relapsed or Refractory Multiple Myeloma PatientsJanssen Pharmaceutical K.K. · completed · Refractory, Multiple Myeloma, Relapse · study director
- Ph2NCT00752661 · An Exploratory Study of Tramadol Hydrochloride in Patients With Osteoarthritis of the Knee or Low Back PainJanssen Pharmaceutical K.K. · completed · Osteoarthritis, Low Back Pain · study director
- Ph3NCT00736957 · A Long-term Efficacy and Safety Study of Tramadol Hydrochloride Plus Acetaminophen (JNS013) in Japanese Participants With Chronic PainJanssen Pharmaceutical K.K. · completed · Chronic Pain · study director
- Ph3NCT00736853 · An Efficacy and Safety Study of Acetaminophen Plus Tramadol Hydrochloride (JNS013) in Participants With Chronic PainJanssen Pharmaceutical K.K. · completed · Pain · study director
- Ph3NCT00727987 · A Safety and Efficacy Study of Golimumab (CNTO 148) in Patients With Active Rheumatoid Arthritis Despite Methotrexate TherapyJanssen Pharmaceutical K.K. · completed · Rheumatoid Arthritis · study director
- Ph3NCT00723528 · An Efficacy and Safety Study of Ustekinumab (CNTO 1275) in Participants With Plaque PsoriasisJanssen Pharmaceutical K.K. · completed · Psoriasis · study director
- Ph3NCT00697918 · Long Term Effectiveness and Safety Study for RWJ-333369 as Adjunctive Therapy in Korean and Japanese Patients With Partial Onset SeizuresSK Life Science, Inc. · completed · Seizures · study director
- Ph3NCT00697762 · Effectiveness and Safety Study for RWJ-333369 as Adjunctive Therapy in Korean and Japanese Patients With Partial Onset SeizuresSK Life Science, Inc. · terminated · Seizures · study director
- Ph1/Ph2NCT00653406 · A Pharmacokinetic and Safety Study of Risperidone Long Acting Injectable in Schizophrenic PatientsJanssen Pharmaceutical K.K. · completed · Schizophrenia · study director
- Ph3NCT00396565 · A Study to Evaluate Effectiveness and Safety of ER OROS Paliperidone in Patients With SchizophreniaJanssen Pharmaceutical K.K. · completed · Schizophrenia · study director
- Ph3NCT00301574 · An Efficacy and Safety Study of Galantamine for the Treatment of Patients With Alzheimer's Disease.Janssen Pharmaceutical K.K. · completed · Alzheimer Disease · study director
- Ph3NCT00287742 · A Study of the Effectiveness and Safety of Risperidone Versus Placebo in the Treatment of Patients With Hallucinations and Delusions Associated With Alzheimer's DiseaseJanssen Pharmaceutical K.K. · terminated · Alzheimer's Disease, Dementia · study director
- Ph2NCT00257023 · An Exploratory Study on the Safety and Effectiveness of Paliperidone in Patients With SchizophreniaJanssen Pharmaceutical K.K. · completed · Schizophrenia · study director
- Ph3NCT00240708 · A Study of the Efficacy and Safety of Long-acting Injectable Risperidone and Risperidone Tablets in Patients With SchizophreniaJanssen Pharmaceutical K.K. · completed · Schizophrenia · study director
- Ph2NCT00216645 · Phase II Clinical Study of Pegylated Liposomal Doxorubicin Hydrochloride Injection as 2nd-line or Later Therapy in Patients With Mullerian Carcinoma (Epithelial Ovarian Carcinoma, Primary Carcinoma of Fallopian Tube, Peritoneal Carcinoma) Having Prior Platinum-Based ChemotherapyJanssen Pharmaceutical K.K. · completed · Ovarian Neoplasms · study director
- Ph2NCT00216658 · Phase II Clinical Trial of Fentanyl Transdermal Matrix Patch, in the Management of Cancer Pain- Assessment of Effectiveness, Safety and Pharmacokinetics -Janssen Pharmaceutical K.K. · completed · Pain, Intractable · study director
- Ph2NCT00216697 · An Extension Study to Provide Bortezomib to Patients With Relapsed or Refractory Multiple Myeloma Who Previously Participated in a Bortezomib Phase I/II Study and Who May Benefit From Re-Treatment With or Continuation of Bortezomib TherapyJanssen Pharmaceutical K.K. · completed · Multiple Myeloma · study director
- Ph3NCT00216684 · Phase III Clinical Trial of Fentanyl Transdermal Matrix Patch, in the Management of Chronic Intractable Pain- Assessment of Effectiveness, Safety and PharmacokineticsJanssen Pharmaceutical K.K. · completed · Pain, Intractable · study director
Grants
NIH projects from RePORTER, fetched 2026-11-12 13:41 UTC. A project is listed only when its grant number is on one of the trials above, or when the awardee institution matches an affiliation the registry gives for this name. Coverage is US federal funding only; UK and EU funders are not searched yet.
No NIH project could be tied to this name by a shared trial or a matching institution.
Most cited trial papers
PubMed returned no clinical-trial papers for this author name in multiple myeloma.